Patient and treatment characteristics of patients who underwent CAR T-cell therapy (n = 124) according to type of BT
| . | . | BT . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | No BT (n = 62) . | ST (n = 45) . | RT (n = 11) . | CMT (n = 6) . | No BT vs ST . | No BT vs RT . | No BT vs CMT . | ST vs RT . | ST vs CMT . | RT vs CMT . |
| Age, y | .55 | .05 | .02 | .15 | .02 | .01 | ||||
| Median | 60 | 60 | 68 | 40.5 | ||||||
| Range | 18-84 | 18-85 | 51-84 | 24-67 | ||||||
| >60 | 32 (52) | 23 (51) | 7 (64) | 2 (33) | 1.00 | .53 | .67 | .52 | .67 | .34 |
| Female sex | 18 (29) | 10 (22) | 2 (18) | 2 (33) | .51 | .72 | 1.00 | 1.00 | .62 | .58 |
| ECOG PS 2-3 | 4 (7) | 10 (22) | 1 (9) | 2 (33) | .02 | .57 | .08 | .43 | .62 | .52 |
| Pathology | .44 | .25 | .27 | .13 | .52 | .04 | ||||
| DLBCL | 49 (79) | 32 (71) | 11 (100) | 3 (50) | ||||||
| TFL | 8 (13) | 10 (22) | 0 (0) | 2 (33) | ||||||
| PMBCL | 5 (8) | 3 (7) | 0 (0) | 1 (17) | ||||||
| Cell of origin | .54 | .10 | .84 | .26 | .67 | .15 | ||||
| GCB | 32 (51) | 28 (62) | 9 (82) | 3 (50) | ||||||
| Non-GCB | 27 (44) | 15 (33) | 1 (9) | 3 (50) | ||||||
| Unknown | 3 (5) | 2 (5) | 1 (9) | 0 (0) | ||||||
| Double expresser | .91 | .18 | .10 | .28 | .16 | .16 | ||||
| Yes | 16 (26) | 13 (29) | 3 (27) | 4 (67) | ||||||
| No | 37 (60) | 25 (56) | 4 (36) | 2 (33) | ||||||
| Unknown | 9 (14) | 7 (15) | 4 (36) | 0 (0) | ||||||
| HGBL-DH/TH | .45 | <.01 | .28 | .07 | .65 | .37 | ||||
| Yes | 7 (11.3) | 9 (20) | 5 (46) | 2 (33) | ||||||
| No | 51 (82) | 33 (73) | 4 (26) | 4 (67) | ||||||
| Unknown | 4 (7) | 3 (7) | 2 (18) | 0 (0) | ||||||
| Stage at apheresis | .17 | 1.00 | .58 | .59 | 1.00 | .52 | ||||
| I/II | 12 (19) | 4 (9) | 2 (18) | 0 (0) | ||||||
| III/IV | 50 (81) | 41 (91) | 9 (82) | 6 (100) | ||||||
| IPI ≥3 | 27 (44) | 31 (69) | 6 (55) | 4 (67) | .01 | .53 | .40 | .48 | 1.00 | 1.00 |
| Bulky disease (≥10 cm) | 11 (18) | 14 (31) | 4 (36) | 4 (67) | .16 | .22 | .02 | .73 | .17 | .23 |
| Lines of prior therapy, n | .90 | .02 | .53 | .01 | .44 | .01 | ||||
| Median | 3 | 3 | 2 | 3 | ||||||
| Range | 2-11 | 2-9 | 2-3 | 2-4 | ||||||
| ≥3 | 43 (69) | 36 (80) | 3 (27) | 5 (83) | .27 | .02 | .66 | <.01 | 1.00 | .05 |
| Serum LDH, IU/L* | ||||||||||
| >ULN | 37 (60) | 38 (86) | 7 (64) | 5 (83) | .02 | .09 | .51 | .09 | .92 | .52 |
| >2× ULN | 8 (13) | 12 (27) | 2 (22) | 4 (67) | .08 | .61 | .01 | 1.00 | .07 | .14 |
| . | . | BT . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | No BT (n = 62) . | ST (n = 45) . | RT (n = 11) . | CMT (n = 6) . | No BT vs ST . | No BT vs RT . | No BT vs CMT . | ST vs RT . | ST vs CMT . | RT vs CMT . |
| Age, y | .55 | .05 | .02 | .15 | .02 | .01 | ||||
| Median | 60 | 60 | 68 | 40.5 | ||||||
| Range | 18-84 | 18-85 | 51-84 | 24-67 | ||||||
| >60 | 32 (52) | 23 (51) | 7 (64) | 2 (33) | 1.00 | .53 | .67 | .52 | .67 | .34 |
| Female sex | 18 (29) | 10 (22) | 2 (18) | 2 (33) | .51 | .72 | 1.00 | 1.00 | .62 | .58 |
| ECOG PS 2-3 | 4 (7) | 10 (22) | 1 (9) | 2 (33) | .02 | .57 | .08 | .43 | .62 | .52 |
| Pathology | .44 | .25 | .27 | .13 | .52 | .04 | ||||
| DLBCL | 49 (79) | 32 (71) | 11 (100) | 3 (50) | ||||||
| TFL | 8 (13) | 10 (22) | 0 (0) | 2 (33) | ||||||
| PMBCL | 5 (8) | 3 (7) | 0 (0) | 1 (17) | ||||||
| Cell of origin | .54 | .10 | .84 | .26 | .67 | .15 | ||||
| GCB | 32 (51) | 28 (62) | 9 (82) | 3 (50) | ||||||
| Non-GCB | 27 (44) | 15 (33) | 1 (9) | 3 (50) | ||||||
| Unknown | 3 (5) | 2 (5) | 1 (9) | 0 (0) | ||||||
| Double expresser | .91 | .18 | .10 | .28 | .16 | .16 | ||||
| Yes | 16 (26) | 13 (29) | 3 (27) | 4 (67) | ||||||
| No | 37 (60) | 25 (56) | 4 (36) | 2 (33) | ||||||
| Unknown | 9 (14) | 7 (15) | 4 (36) | 0 (0) | ||||||
| HGBL-DH/TH | .45 | <.01 | .28 | .07 | .65 | .37 | ||||
| Yes | 7 (11.3) | 9 (20) | 5 (46) | 2 (33) | ||||||
| No | 51 (82) | 33 (73) | 4 (26) | 4 (67) | ||||||
| Unknown | 4 (7) | 3 (7) | 2 (18) | 0 (0) | ||||||
| Stage at apheresis | .17 | 1.00 | .58 | .59 | 1.00 | .52 | ||||
| I/II | 12 (19) | 4 (9) | 2 (18) | 0 (0) | ||||||
| III/IV | 50 (81) | 41 (91) | 9 (82) | 6 (100) | ||||||
| IPI ≥3 | 27 (44) | 31 (69) | 6 (55) | 4 (67) | .01 | .53 | .40 | .48 | 1.00 | 1.00 |
| Bulky disease (≥10 cm) | 11 (18) | 14 (31) | 4 (36) | 4 (67) | .16 | .22 | .02 | .73 | .17 | .23 |
| Lines of prior therapy, n | .90 | .02 | .53 | .01 | .44 | .01 | ||||
| Median | 3 | 3 | 2 | 3 | ||||||
| Range | 2-11 | 2-9 | 2-3 | 2-4 | ||||||
| ≥3 | 43 (69) | 36 (80) | 3 (27) | 5 (83) | .27 | .02 | .66 | <.01 | 1.00 | .05 |
| Serum LDH, IU/L* | ||||||||||
| >ULN | 37 (60) | 38 (86) | 7 (64) | 5 (83) | .02 | .09 | .51 | .09 | .92 | .52 |
| >2× ULN | 8 (13) | 12 (27) | 2 (22) | 4 (67) | .08 | .61 | .01 | 1.00 | .07 | .14 |
Values are n (%) unless otherwise noted. P values in bold indicate statistical significance (≤.05).
LDH data unavailable for 5 patients in the no BT (n = 2), ST (n = 1), and RT (n = 2) cohorts.